the staff of the Ridgewood blog
New Brunswick NJ, U.S. Food and Drug Administration (FDA) staff said in documents published on Wednesday, that Johnson & Johnson’s one-shot COVID-19 vaccine appeared safe and effective in trials, paving the way for its approval for emergency use (EUA) .
The FDA’s panel of independent experts meets on Friday to decide whether to approve the shot. While it is not bound to follow the advice of its experts, the FDA did so when authorizing the Pfizer Inc and Moderna Inc vaccines.
J&J’s vaccine was 66% effective in preventing COVID-19against multiple variants in a global trial involving nearly 44,000 people, the company said last month.
Its effectiveness varied from 72% in the United States to66% in Latin America and 57% in South Africa, where a new variant has spread, though the vaccine was 85% effective overall in stopping severe cases of the disease.
Pending authorization from the Food and Drug Administration, a Johnson & Johnson executive on Tuesday said the company expected to ship nearly 4 million doses of the vaccine .
